4D Molecular Therapeutics Insider Sold Shares Worth $753,937, According to a Recent SEC Filing

MT newswire2026/10/07 21:18

05:18 PM EDT, 10/07/2026 (MT Newswires) -- David Kirn, Director, President and Chief Executive Officer, on October 05, 2026, sold 58,333 shares in 4D Molecular Therapeutics (FDMT) for $753,937. Following the Form 4 filing with the SEC, Kirn has control over a total of 709,153 common shares of the company, with 709,153 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1650648/000119312526417068/xslF345X05/ownership.xml

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Google (GOOGL.US) warns that new Australian cybersecurity regulations may cut off minors' access to Gmail

Google stated that a new cybersecurity bill in Australia could prevent minors from using Gmail.

智通财经•2026/11/09 07:32

Canaccord Genuity: Lowers Oklo's target price to $66

格隆汇•2026/11/09 07:01

Bernstein: Huang Renxun's Controversy May Increase Nvidia's Regulatory Risks, but Maintains $400 Price Target

Cointime•2026/11/09 06:43

"No-drill dental filling" company vVardis (VVVV.US) launches a $214 million US IPO, scheduled to be priced this week.

Dental treatment company vVardis has announced the terms for its $214 million US IPO.

智通财经•2026/11/09 06:41